AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35694835 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐assembling peptide (P11‐4)
Number of subjects: 40
Study 35694835 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium fluoride (NaF)
Number of subjects: 40
Study 35694835 — intervention group
Group type: COMPARATOR
Intervention: artificial saliva (AS)
Number of subjects: 40
Study 34534909 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA model based on MRI findings
Number of subjects: 357
Study 34534909 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA model
Number of subjects: 357
Study 32592261 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 20℃, 50% rH, FiO2 : 20.9%; sea level)
Number of subjects: 10
Study 32592261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (HYP; 20℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m)
Number of subjects: 10
Study 32592261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot (HOT; 35℃, 50% rH, FiO2 : 20.9%; sea level)
Number of subjects: 10
Study 32592261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot + Hypoxia (HH; 35℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m)
Number of subjects: 10
Study 34293998 — intervention group
Group type: EXPERIMENTAL
Intervention: Music selected by the patient (n=35)
Number of subjects: 106
Study 34293998 — intervention group
Group type: EXPERIMENTAL
Intervention: Music selected by the physician (n=36)
Number of subjects: 106
Study 34293998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music, n=35)
Number of subjects: 106
Study 34293998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients answering in Arabic
Number of subjects: 106
Study 32975853 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin infusion
Number of subjects: 8
Study 32975853 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 36461123 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation-optimised video with patients giving information about their mostly positive therapy outcomes (positive model)
Number of subjects: 158
Study 36461123 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with instructions to focus on differences (discrepancy group)
Number of subjects: 158
Study 36461123 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with instructions to focus on similarities (similarity group)
Number of subjects: 158
Study 36461123 — intervention group
Group type: COMPARATOR
Intervention: Control group watched a video with patients giving information about their symptoms
Number of subjects: 158
Study 34569641 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 362
Study 34569641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 33252379 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuvirtide plus ritonavir-boosted lopinavir (ABT group)
Number of subjects: 175
Study 33252379 — intervention group
Group type: COMPARATOR
Intervention: WHO-recommended second-line treatment (NRTI group)
Number of subjects: 175
Study 33252379 — intervention group
Group type: COMPARATOR
Intervention: NRTI group (specifically those receiving tenofovir disoproxil fumarate)
Number of subjects: 175
Study 33252379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ABT and NRTI)
Number of subjects: 175
Study 33829710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (19 times)
Number of subjects: 93
Study 33829710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (15 times)
Number of subjects: 93
Study 33829710 — intervention group
Group type: COMPARATOR
Intervention: EPI (18 times)
Number of subjects: 93
Study 33829710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG groups (combined)
Number of subjects: 93
Study 33829710 — intervention group
Group type: EXPERIMENTAL
Intervention: CUETO scoring model and EORTC risk tables
Number of subjects: 93
Study 32228533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 71
Study 32228533 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-developed stress reduction intervention (LSR)
Number of subjects: 71
Study 32228533 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 71
Study 33271298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet + fennel (2 capsule/day)
Number of subjects: 64
Study 33271298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric standardize diet + fennel (2 capsule/day)
Number of subjects: 64
Study 33271298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet + placebo
Number of subjects: 64
Study 33271298 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric standardize diet + placebo
Number of subjects: 64
Study 32371987 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN discontinuation at 100 ml/kg/day
Number of subjects: 0
Study 32371987 — intervention group
Group type: COMPARATOR
Intervention: TPN discontinuation at 140 ml/kg/day
Number of subjects: 0
Study 34921934 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Assessment and Management Intervention (SAMI)
Number of subjects: 179
Study 34921934 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 179
Study 34159620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion (group DEX)
Number of subjects: 12
Study 34159620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion combined with vatinoxan 130 µg kg−1 followed by 40 µg kg−1 h−1 infusion (group VAT)
Number of subjects: 12
Study 32778721 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 20
Study 32778721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIIT)
Number of subjects: 20
Study 35234561 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 100 µg
Number of subjects: 166
Study 35234561 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 300 µg
Number of subjects: 166
Study 35234561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 33475844 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescent cholangiography (NIFC) with preoperative administration of indocyanine green (ICG)
Number of subjects: 0
Study 33475844 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of specific standardized steps for NIFC
Number of subjects: 0
Study 32859156 — intervention group
Group type: EXPERIMENTAL
Intervention: StayFitLonger programme (experimental intervention)
Number of subjects: 128
Study 32859156 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 128
Study 35508427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala coloring for 30 min during premedication before chemotherapy
Number of subjects: 84
Study 35508427 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 84
Study 33638143 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network analysis on stone clearance rate in training group (813 cases)
Number of subjects: 1182
Study 33638143 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network analysis on stone clearance rate in testing group (270 cases)
Number of subjects: 1182
Study 32815423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0
Study 32815423 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide 7 or 14 mg
Number of subjects: 0
Study 32815423 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 0
Study 36069505 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml ropivacaine 0.5%
Number of subjects: 16
Study 36069505 — intervention group
Group type: COMPARATOR
Intervention: 20 ml ropivacaine 0.5%
Number of subjects: 16
Study 33750239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-associated human chemosignals (three doses)
Number of subjects: 67
Study 33750239 — intervention group
Group type: COMPARATOR
Intervention: Neutral sweat
Number of subjects: 67
Study 33750239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-associated human chemosignals
Number of subjects: 67
Study 35609214 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 60
Study 35609214 — intervention group
Group type: EXPERIMENTAL
Intervention: Community living after rehabilitation
Number of subjects: 60
Study 35609214 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent walking
Number of subjects: 60
Study 35609214 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair use
Number of subjects: 60
Study 35609214 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed improvement
Number of subjects: 60
Study 33893329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation of the left ventrolateral PFC (1.5 mA for 20 min)
Number of subjects: 246
Study 33893329 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 246
Study 33893329 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent bilateral stimulation of the ventrolateral PFC (regardless of polarity direction)
Number of subjects: 246
Study 33893329 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory stimulation of occipital cortex
Number of subjects: 246
Study 32839029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h for 30 min before the end of surgery) in groups DD (Dex), ID (Dex), and II(Dex)
Number of subjects: 210
Study 32839029 — intervention group
Group type: COMPARATOR
Intervention: Control group (II) without dexmedetomidine
Number of subjects: 210
Study 35580961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered shaped double‐threaded design (TS/DT)
Number of subjects: 28
Study 35580961 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical shaped single‐threaded design (CS/ST)
Number of subjects: 28
Study 32375501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized minimal acupuncture at LI4 for 5 seconds (group A, n=48)
Number of subjects: 147
Study 32375501 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardized individual acupuncture with a maximum of five insertions for up to 30 seconds (group B, n=49)
Number of subjects: 147
Study 32375501 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (group C, n=48)
Number of subjects: 147
Study 32622074 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling (US) with usual oral hygiene instructions
Number of subjects: 22
Study 32622074 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with ultrasonic scaling (US)
Number of subjects: 22
Study 36451150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esketamine, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Number of subjects: 0
Study 36451150 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Number of subjects: 0
Study 34169628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 80
Study 34169628 — intervention group
Group type: COMPARATOR
Intervention: Carbon-assisted Q-switched Nd: YAG laser treatment
Number of subjects: 80
Study 36372958 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 70
Study 32201062 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF membrane
Number of subjects: 32
Study 32201062 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (Control)
Number of subjects: 32
Study 33351452 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative 500 mg dose of methylprednisolone
Number of subjects: 151
Study 34351377 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 354
Study 34351377 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing at 12 months
Number of subjects: 354
Study 34351377 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV type-specific persistence at 12-month follow-up
Number of subjects: 354
Study 34351377 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 354
Study 32969128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated for localised prostate cancer
Number of subjects: 287
Study 32969128 — intervention group
Group type: COMPARATOR
Intervention: Control group from the general population
Number of subjects: 287
Study 33032868 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 440
Study 33032868 — intervention group
Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 440
Study 33032868 — intervention group
Group type: COMPARATOR
Intervention: No message
Number of subjects: 440
Study 36111475 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot group (87 cases, PKP assisted by modified orthopedic robot)
Number of subjects: 155
Study 36111475 — intervention group
Group type: COMPARATOR
Intervention: C-arm group (68 cases, PKP assisted by C-arm X-ray fluoroscopy)
Number of subjects: 155
Study 33054012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 33054012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electrotherapy
Number of subjects: 0
Study 33054012 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic mechanotherapy
Number of subjects: 0
Study 35210126 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor (CGF) applied to the mental nerve on one side
Number of subjects: 26
Study 35210126 — intervention group
Group type: COMPARATOR
Intervention: Control (no CGF applied)
Number of subjects: 26
Study 32180528 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with depression program (individual psychoeducation based on the Neuman systems model, involving cognitive behavioral therapy techniques) administered at six sessions
Number of subjects: 0
Study 33725408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low immunosuppression (LI) with tacrolimus monotherapy
Number of subjects: 167
Study 33725408 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 167
Study 33725408 — intervention group
Group type: EXPERIMENTAL
Intervention: E+ patients (received SOC)
Number of subjects: 167
Study 33415860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoyi Sanjiao acupuncture and moxibustion
Number of subjects: 154
Study 33415860 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chinese and Western medicine (Control)
Number of subjects: 154
Study 33415860 — intervention group
Group type: COMPARATOR
Intervention: Comparison between treatment and control groups
Number of subjects: 154
Study 35169165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 20
Study 35169165 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 35169165 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1(7-36)-amide
Number of subjects: 20
Study 35169165 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 20
Study 35169165 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1/GIP combination
Number of subjects: 20
Study 35169165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34788325 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate empirical antibiotic treatment
Number of subjects: 509
Study 34788325 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 509
Study 35700592 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (120 mg/d)
Number of subjects: 101
Study 35700592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 32544416 — intervention group
Group type: EXPERIMENTAL
Intervention: Function Acquisition Speed Test (FAST) assessments
Number of subjects: 16
Study 37553030 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg every 12 weeks
Number of subjects: 897
Study 33646989 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 128
Study 33646989 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 128
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% citric acid-modified 2% chlorhexidine (CAmCHX)
Number of subjects: 53
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 53
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CAmCHX
Number of subjects: 53
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1%, 6%, and 10% CAmCHX
Number of subjects: 53
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% and 10% CAmCHX
Number of subjects: 53
Study 33353912 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 53
Study 33353912 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 53
Study 35679030 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine ω-3 fatty acids, 1 g per day
Number of subjects: 23523
Study 35679030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23523
Study 33636278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy with external beam radiation therapy (RT) for 6 months
Number of subjects: 64
Study 36180323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral paresthesia coverage
Number of subjects: 30
Study 36180323 — intervention group
Group type: COMPARATOR
Intervention: Contralateral paresthesia coverage
Number of subjects: 30
Study 33331182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100-mg once-daily for 3-5 days (acute uncomplicated UTI)
Number of subjects: 135
Study 33331182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100-mg twice daily for 10-14 days (complicated UTI)
Number of subjects: 135
Study 33331182 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500-mg once-daily for 3-5 days (acute uncomplicated UTI)
Number of subjects: 135
Study 33331182 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500-mg once-daily for 10-14 days (complicated UTI)
Number of subjects: 135
Study 35995816 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin administration to maintain a level of 80-120%
Number of subjects: 46
Study 35995816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antithrombin supplementation)
Number of subjects: 46
Study 33430604 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus eptifibatide
Number of subjects: 13229
Study 33430604 — intervention group
Group type: COMPARATOR
Intervention: Otamixaban
Number of subjects: 13229
Study 32386891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich vegetables
Number of subjects: 30
Study 32386891 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 30
Study 36418930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 34
Study 36418930 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (control)
Number of subjects: 34
Study 36418930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both smokers and nonsmokers (before and after treatment)
Number of subjects: 34
Study 32485623 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 136
Study 34789008 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 291
Study 34789008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 33706830 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 1090
Study 33706830 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 1090
Study 33706830 — intervention group
Group type: COMPARATOR
Intervention: No writing
Number of subjects: 1090
Study 32081030 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt‐1/PlGF ratio ≥38
Number of subjects: 295
Study 32081030 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt‐1 and PlGF assays
Number of subjects: 295
Study 34637519 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV stabilized prefusion F subunit vaccine (RSVpreF) with Tdap
Number of subjects: 0
Study 34637519 — intervention group
Group type: COMPARATOR
Intervention: Tdap alone
Number of subjects: 0
Study 32521097 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate narrative reconstruction intervention
Number of subjects: 30
Study 32521097 — intervention group
Group type: COMPARATOR
Intervention: Delayed narrative reconstruction intervention
Number of subjects: 30
Study 35849445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training (In/Ex-SC)
Number of subjects: 51
Study 35849445 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 51
Study 34370971 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd/BNT
Number of subjects: 830
Study 34370971 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT/ChAd
Number of subjects: 830
Study 34370971 — intervention group
Group type: COMPARATOR
Intervention: ChAd/ChAd
Number of subjects: 830
Study 34370971 — intervention group
Group type: COMPARATOR
Intervention: BNT/BNT
Number of subjects: 830
Study 32342642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (5 g/day containing 2 g/day eicosapentaenoic acid and 1 g/day docosahexaenoic acid)
Number of subjects: 24
Study 32342642 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation (5 g/day)
Number of subjects: 24
Study 33091706 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 2 mg/kg intravenous infusion
Number of subjects: 248
Study 33091706 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 248
Study 32485664 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min/day pedaling group
Number of subjects: 20
Study 32485664 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min/day pedaling group
Number of subjects: 20
Study 32485664 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 min/day pedaling group
Number of subjects: 20